Date: 2016-03-23
Type of information: Restructuring
Compound:
Company: PTC Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: restructuring
Action mechanism:
Disease:
Details: * On March 23, 2016, PTC Therapeutics announced that the company is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S. This reduction is part of PTC's program intended to optimally manage operating expenses following its recent setback related to the Refuse to File letter received from the FDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC remains focused on the global development of Translarna® and commercialization outside of the U.S. for nmDMD. In parallel, PTC intends to work with the FDA to determine the best path forward to bring Translarna to patients in the U.S. PTC plans to complete this workforce reduction by June 30, 2016 and expects to incur related employee severance and benefit costs of approximately $2.5 million.
Financial terms:
Latest news:
